Bild

Leveraging the natural tolerance induction capabilities of the liver

Topas Therapeutics is focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by utilizing the liver’s natural immunology capabilities, targeting liver sinusoidal endothelial cells (LSECs), which generate tolerance against bloodborne antigens. Topas Particle Conjugates mimic such bloodborne antigens and follow their natural processing in LSECs, including the generation of long-lasting antigen-specific regulatory T cells (Tregs), a critically important type of immune cell for maintaining immune tolerance. Topas’ novel technology is enabling the development of new therapeutic solutions for challenging diseases.

Latest News

2022-02-15 – Press release

Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

read more …

2021-07-29 – Press release

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

read more …

2020-10-19 – Press release

Topas Therapeutics erhält EUR 22 Mio. (USD 26 Mio.) aus Serie-B-Finanzierungsrunde

read more …

2020-10-19 – Press release

Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing

read more …

2020-10-19 – Press release

Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer

read more …